Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer - PubMed (original) (raw)
Review
Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer
S R Johnston. Lancet Oncol. 2001 Jan.
Abstract
Activating oncogenic mutations of the RAS gene are common in cancer, occurring in 30% of solid tumours in adults. Inhibitors of the enzyme farnesyl protein transferase prevent a key step in the post-translational processing of the RAS protein, and were developed initially as a therapeutic strategy to inhibit cell signalling in RAS-transformed cells. As more has been learnt about the biological effects of farnesyl transferase inhibitors on cancer cells, it has become increasingly clear that tumours without oncogenic RAS mutations may also be targets for farnesyl transferase inhibitor therapy. Encouraging results from phase I and II clinical trials have emerged, creating both enthusiasm and new challenges for the optimum clinical development of this important new class of anticancer drug.
Similar articles
- Farnesyl transferase inhibitors--a novel therapy for breast cancer.
Johnston SR, Kelland LR. Johnston SR, et al. Endocr Relat Cancer. 2001 Sep;8(3):227-35. doi: 10.1677/erc.0.0080227. Endocr Relat Cancer. 2001. PMID: 11566614 Review. - Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J, Pradines A, Favre G. Mazieres J, et al. Cancer Lett. 2004 Apr 8;206(2):159-67. doi: 10.1016/j.canlet.2003.08.033. Cancer Lett. 2004. PMID: 15013521 Review. - Farnesyl transferase inhibitors as anticancer agents.
Haluska P, Dy GK, Adjei AA. Haluska P, et al. Eur J Cancer. 2002 Sep;38(13):1685-700. doi: 10.1016/s0959-8049(02)00166-1. Eur J Cancer. 2002. PMID: 12175684 Review. - [Development of farsenyl transferase inhibitors as anticancer agents].
Cestac P, Doisneau-Sixou S, Favre G. Cestac P, et al. Ann Pharm Fr. 2005 Jan;63(1):76-84. doi: 10.1016/s0003-4509(05)82254-0. Ann Pharm Fr. 2005. PMID: 15803104 Review. French. - [Farnesyl transferase inhibitors: one target may be found in another].
Mazières J, Pradines A, Favre G. Mazières J, et al. Med Sci (Paris). 2003 Feb;19(2):211-6. doi: 10.1051/medsci/2003192211. Med Sci (Paris). 2003. PMID: 12836615 Review. French.
Cited by
- Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy.
Tatli O, Dinler Doganay G. Tatli O, et al. Molecules. 2021 Dec 14;26(24):7561. doi: 10.3390/molecules26247561. Molecules. 2021. PMID: 34946644 Free PMC article. Review. - Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data.
Saunders AS, Bender DE, Ray AL, Wu X, Morris KT. Saunders AS, et al. PLoS One. 2021 Feb 19;16(2):e0247233. doi: 10.1371/journal.pone.0247233. eCollection 2021. PLoS One. 2021. PMID: 33606788 Free PMC article. - The microRNA-200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2.
Carter JV, O'Brien SJ, Burton JF, Oxford BG, Stephen V, Hallion J, Bishop C, Galbraith NJ, Eichenberger MR, Sarojini H, Hattab E, Galandiuk S. Carter JV, et al. Oncol Lett. 2019 Oct;18(4):3994-4007. doi: 10.3892/ol.2019.10753. Epub 2019 Aug 16. Oncol Lett. 2019. PMID: 31565080 Free PMC article. - Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).
Torres-Collado AX, Knott J, Jazirehi AR. Torres-Collado AX, et al. Cancers (Basel). 2018 May 24;10(6):157. doi: 10.3390/cancers10060157. Cancers (Basel). 2018. PMID: 29795041 Free PMC article. Review. - The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study.
Jin Y, Li L, Yang Z, Liu M, Guo H, Shen W. Jin Y, et al. Oncotarget. 2017 Apr 11;8(15):24635-24643. doi: 10.18632/oncotarget.15601. Oncotarget. 2017. PMID: 28445950 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials